March, 29 2023
PAR-22-049 - Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
National Cancer Institute (NCI)
This Notice corrects the matrix of Application Due Dates for PAR-22-049 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)".
The following section of PAR-22-049 has been corrected:
Currently, it reads:
Application Due Dates | Review and Award Cycles | ||||
---|---|---|---|---|---|
New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
January 11, 2022 | January 11, 2022 | Not Applicable | July 2022 | October 2022 | December 2022 |
June 07, 2022 | June 07, 2022 | Not Applicable | November 2022 | January 2023 | April 2023 |
September 13, 2022 | September 13, 2022 | Not Applicable | March 2023 | May 2023 | July 2023 |
January 11, 2023 | March 05, 2023 * | Not Applicable | July 2023 | October 2023 | December 2023 |
June 07, 2023 | June 07, 2023 | Not Applicable | November 2023 | January 2024 | April 2024 |
September 13, 2023 | September 13, 2023 | Not Applicable | March 2024 | May 2024 | July 2024 |
January 11, 2024 | March 05, 2024 * | Not Applicable | July 2024 | October 2024 | December 2024 |
June 07, 2024 | June 07, 2024 | Not Applicable | November 2024 | January 2025 | April 2025 |
September 13, 2024 | September 13, 2024 | Not Applicable | March 2025 | May 2025 | July 2025 |
Corrected to read (in bold italics):
Application Due Dates | Review and Award Cycles | ||||
---|---|---|---|---|---|
New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
January 11, 2022 | January 11, 2022 | Not Applicable | July 2022 | October 2022 | December 2022 |
June 07, 2022 | June 07, 2022 | Not Applicable | November 2022 | January 2023 | April 2023 |
September 13, 2022 | September 13, 2022 | Not Applicable | March 2023 | May 2023 | July 2023 |
January 11, 2023 | March 05, 2023 * | Not Applicable | July 2023 | October 2023 | December 2023 |
June 07, 2023 | June 07, 2023 | Not Applicable | November 2023 | January 2024 | April 2024 |
September 13, 2023 | September 13, 2023 | Not Applicable | March 2024 | May 2024 | July 2024 |
January 11, 2024 | January 11. 2024 | Not Applicable | July 2024 | October 2024 | December 2024 |
June 07, 2024 | June 07, 2024 | Not Applicable | November 2024 | January 2025 | April 2025 |
September 13, 2024 | September 13, 2024 | Not Applicable | March 2025 | May 2025 | July 2025 |
All other aspects of PAR-22-049 remain unchanged.
Scientific/Research Contact(s)
Lokesh Agrawal, PhD
National Cancer Institute (NCI)
Telephone:240-276-5718
Email: [email protected]
Abhi Rao, PhD
National Cancer Institute (NCI)
Telephone: 240-276-5715
Email: [email protected]
Peer Review Contact(s)
Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]
Financial/Grants Management Contact(s)
Shane Woodward
National Cancer Institute (NCI)
Telephone: 240-276-6303
Email: [email protected]